Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Ixiaro
Generic Name
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DrugBank Accession Number
DB10769
Background

Not Available

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Japanese encephalitis vaccine
  • Japanese encephalitis vaccine IC51
  • Japanese encephalitis virus (inactivated)
  • Japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated)
External IDs
  • IC-51
  • IC51

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
IxiaroInjection, suspension6 AUIntramuscularValneva Austria Gmb H2020-12-23Not applicableEU flag
IxiaroInjection, suspension6 [arb'U]/0.5mLIntramuscularValneva Scotland Ltd.2009-03-30Not applicableUS flag
IxiaroInjection, suspension6 AUIntramuscularValneva Austria Gmb H2020-12-23Not applicableEU flag
IxiaroInjection, suspension6 ug/0.5mLIntramuscularValneva Scotland Ltd.2009-03-30Not applicableUS flag
IxiaroSuspension6 mcg / 0.5 mLIntramuscularValneva Austria Gmbh2009-12-29Not applicableCanada flag
IxiaroInjection, suspension6 ug/0.5mLIntramuscularVetter Pharma Fertigung GmbH & Co. KG2009-03-30Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
DZ854I04ZE
CAS number
Not Available

References

General References
Not Available
RxNav
1300779

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceEncephalitis, Japanese B / Japanese Encephalitis Vaccine1
4CompletedBasic ScienceHumoral and Cellular Immune Responses1
4CompletedPreventionEncephalitis1
4CompletedPreventionEncephalitis, Japanese B2
4CompletedPreventionEncephalitis, Japanese B / Measles / Mumps / Rubella1
4Enrolling by InvitationPreventionEncephalitis, Japanese B / Vaccine Preventable Diseases / Vaccine Reaction1
4RecruitingPreventionJapanese Encephalitis Vaccine1
4Unknown StatusPreventionHand, Foot and Mouth Disease (HFMD)1
3Active Not RecruitingPreventionJapanese Encephalitis Virus Disease1
3CompletedOtherEncephalitis, Japanese B1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution1 ml
Injection, suspensionIntramuscular6 AU
Injection, suspensionIntramuscular6 [arb'U]/0.5mL
Injection, suspensionIntramuscular6 ug/0.5mL
Injection, suspensionIntramuscular; Subcutaneous6 MCG
SuspensionIntramuscular6 mcg / 0.5 mL
Injection, suspensionIntramuscular6 mcg/0.5mL
InjectionSubcutaneous
Injection, powder, lyophilized, for solution0.5 ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:04 / Updated on October 19, 2021 07:39